Rivastigmine

[MAF] Rivastigmine Transdermal Patch 4.6 mg/24 hr, 9.5 mg/24 hr

1. Treatment of moderately severe dementia associated with Parkinson’s disease in patients who have behavioural symptoms

2. Treatment of moderately severe dementia associated with Alzheimer’s disease in patients who have behavioural symptoms

[MAF] Rivastigmine Transdermal Patch 13.3 mg/24 hr

1. Treatment of moderately severe dementia associated with Alzheimer’s disease in patients who have behavioural symptoms.

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

05/02/2018 Rivastigmine for the treatment of dementia associated with Alzheimer’s disease or Parkinson’s disease

The Ministry of Health’s Drug Advisory Committee has recommended:

• Rivastigmine patch formulation (4.6mg/24h and 9.5mg/24h) for the treatment of moderately severe dementia, and behavioural symptoms of dementia, associated with Parkinson’s disease.

• Rivastigmine patch formulation (4.6mg/24h, 9.5mg/24h and 13.3mg/24h) for the treatment of moderately severe dementia, and behavioural symptoms of dementia, associated with Alzheimer’s disease.

Conditions should be confirmed by a specialist physician (geriatrician, neurologist or psychiatrist) with experience in the treatment of dementia.

Treatment should be continued only when it is considered to be having a worthwhile effect on cognitive, global, functional or behavioural symptoms.

Subsidy status

[R] Rivastigmine patch formulation (4.6mg/24h, 9.5mg/24h and 13.3mg/24h) is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications.

[R] Rivastigmine should be used in line with the clinical criteria in the MAF checklist for initial and continuing prescriptions. Treatment effect has to be re-assessed 6-monthly before further MAF assistance is granted for additional prescriptions.

[NR] MAF assistance does not apply to rivastigmine capsules (1.5mg, 3mg, 4.5mg and 6mg).

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration